Payload Information

General Information of This Payload
Payload ID
PAY0LXBQB
Name
Sodium butyrate
Synonyms
SODIUM BUTYRATE; 156-54-7; Sodium butanoate; Butyric acid sodium salt; Butanoic acid, sodium salt; Butyric acid, sodium salt; Butyrate sodium; Sodium n-butyrate; sodium;butanoate; Sodium propanecarboxylate; Butanoic acid sodium salt; C4H7NaO2; CCRIS 7068; HSDB 5655; Sodium butyrate (USP); Sodium butyrate [USP]; TPA/BA; Butanoic acid, sodium salt (1:1); EINECS 205-857-6; NSC 174280; UNII-8RAS91C36W; 8RAS91C36W; DTXSID3037672; CHEBI:64103; NSC-174280; Tetradecanoyl phorbol acetate/ sodium butyrate; Butyric Acid, Na; tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA); CHEMBL62381; NSC174280; SODIUM BUTYRATE-3,3,4,4,4-D5; NCGC00167555-01; MFCD00002816; sodiumbutyrate; 204244-79-1; Sodium butyrate, 98%; D0I7IB; C4H8O2.Na; SCHEMBL30148; SODIUM BUTYRATE [HSDB]; DTXCID1017672; HY-B0350A; SODIUM BUTYRATE [USP-RS]; SODIUM BUTYRATE [WHO-DD]; MFBOGIVSZKQAPD-UHFFFAOYSA-M; HMS3650B09; BCP31813; Butanoicacidsodiumsalt butyratesodium; Tox21_112550; HB1399; OR8783; s1999; Sodium butyrate, >=98.5% (GC); Sodium butyrate, >=99.0% (GC); AKOS003051490; AKOS015899795; CCG-266046; CS-3924; SODIUM BUTYRATE [USP MONOGRAPH]; AS-13929; CAS-156-54-7; LS-48173; FT-0660356; FT-0694101; D08998; AB01274751-01; Sodium butyrate, Vetec(TM) reagent grade, 99%; A921858; Q305004; Sodium butyrate, certified reference material, TraceCERT(R); Sodium butyrate, United States Pharmacopeia (USP) Reference Standard
   Click to Show/Hide
Target(s) Histone deacetylase 1 (HDAC1)
 Target Info 
Structure
Formula
C4H7NaO2
Isosmiles
CCCC(=O)[O-].[Na+]
PubChem CID
5222465
InChI
InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1
InChIKey
MFBOGIVSZKQAPD-UHFFFAOYSA-M
IUPAC Name
sodium;butanoate
Pharmaceutical Properties
Molecule Weight
110.09
Polar area
40.1
Complexity
53.7
xlogp Value
.
Heavy Count
7
Rot Bonds
2
Hbond acc
2
Hbond Donor
0
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1000000 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1000000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[1]
Half Maximal Inhibitory Concentration (IC50) 1000000 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [2]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1000000 nM
UACC-257 cells
Melanoma
CVCL_1779 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10568175.09 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10641430.18 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1386755.83 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[1]
Half Maximal Inhibitory Concentration (IC50) 140000 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[3]
Half Maximal Inhibitory Concentration (IC50) 1400000 nM
BT-20 cells
Invasive breast carcinoma of no special type
CVCL_0178 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1651961.8 nM
UACC-62 cells
Melanoma
CVCL_1780 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18706821.4 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18706821.4 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 1990673.34 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
[1]
Half Maximal Inhibitory Concentration (IC50) 2000000 nM
Human umbilical vein endothelial cells(HUVEC)
Normal
Undisclosed [2]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2046444.64 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2306747.19 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2371373.71 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2393315.76 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2421029.05 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 242661.01 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 251188.64 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2517676.93 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2766941.65 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2999162.52 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3026913.43 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3443499.31 nM
NCI-H522 cells
Non-small cell lung carcinoma
CVCL_1567 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3459393.78 nM
NCI-H322M cells
Minimally invasive lung adenocarcinoma
CVCL_1557 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3467368.5 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3523708.71 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3580964.37 nM
MDA-N cells
Breast carcinoma
CVCL_1910 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3732501.58 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3971915.49 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 399944.75 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3999447.5 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[1]
Half Maximal Effective Concentration (EC50) 4 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[5]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4168693.83 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4395416.15 nM
A498 cells
Renal carcinoma
CVCL_1056 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4446312.67 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4466835.92 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4720630.41 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4786300.92 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[1]
Half Maximal Inhibitory Concentration (IC50) 500000 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5308844.44 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 533334.9 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 543250.33 nM
Malme-3M cells
Melanoma
CVCL_1438 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5457578.61 nM
M14 cells
Melanoma
CVCL_1395 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5675446.05 nM
HOP-92 cells
Non-small cell lung carcinoma
CVCL_1286 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5714786.37 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[1]
Half Maximal Inhibitory Concentration (IC50) 600000 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6251726.93 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 635330.93 nM
SK-MEL-5 cells
Cutaneous melanoma
CVCL_0527 
[1]
Half Maximal Inhibitory Concentration (IC50) 700000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[4]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7095777.68 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 719448.98 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 721107.48 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7211074.79 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7655966.07 nM
SF-295 cells
Glioblastoma
CVCL_1690 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7834296.43 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 788860.12 nM
SR cells
Leukemia
CVCL_1711 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7979946.87 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
[1]
Half Maximal Inhibitory Concentration (IC50) 800000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[6]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8035261.22 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8165823.71 nM
SNB-19 cells
Astrocytoma
CVCL_0535 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8279421.64 nM
SF268 cells
Astrocytoma
CVCL_1689 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8394599.87 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 843334.76 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9440608.76 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9682778.56 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9908319.45 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[1]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 PubChem BioAssay data set.
Ref 2 Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes. J Biol Chem. 2007 Sep 28;282(39):28408-28418. doi: 10.1074/jbc.M703586200. Epub 2007 Aug 3.
Ref 3 Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem. 1999 Jul 29;42(15):3001-3. doi: 10.1021/jm980565u.
Ref 4 From natural products to HDAC inhibitors: An overview of drug discovery and design strategy. Bioorg Med Chem. 2021 Dec 15;52:116510. doi: 10.1016/j.bmc.2021.116510. Epub 2021 Nov 10.
Ref 5 Synthesis and NMR-driven conformational analysis of taxol analogues conformationally constrained on the C13 side chain. J Med Chem. 2001 May 10;44(10):1576-87. doi: 10.1021/jm001103v.
Ref 6 Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorg Med Chem. 2009 Jul 15;17(14):5219-28. doi: 10.1016/j.bmc.2009.05.042. Epub 2009 May 23.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.